Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

Adnan Aydiner



Author of

  • +

    P2.01 - Advanced NSCLC (ID 618)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Advanced NSCLC
    • Presentations: 1
    • +

      P2.01-003 - Does Astragalus Membranaceus Root Extract Have Any Survival Benefit for Metastatic Non-Small Cell Lung Cancer? (ID 7536)

      09:00 - 09:00  |  Presenting Author(s): Adnan Aydiner

      • Abstract

      Background:
      We aimed to determine whether Astragalus membranaceus root extract (AmE), which has immunomodulatory activities mainly on macrophages and Th1 type immune response, improve the overall survival (OS) of patients with metastatic non-small cell lung cancer (NSCLC).

      Method:
      The medical charts of 117 patients with metastatic NSCLC were retrospectively assessed. Thirty-four patients (A group) using AmE during systemic anti-cancer treatment were compared with 83 controls (C group) who did not use AmE following the diagnosis of NSCLC. The histological subtype, performance status, age, gender, smoking status, comorbidities, chemotherapeutics (CT), and erlotinib that were received in any line of treatment were recorded. We compared the OS of the patients in the A and C groups.

      Result:
      The median (±SD) age of the patients was 61(±7) years and all patients were administered systemic treatment (CT or erlotinib). The histological subtype, performance status, age, gender, smoking status, comorbidities, usage of different type of CT agents and erlotinib were similar in the A and C groups. The median follow-up period was longer for the A group than the C group (18 vs 11 months, p <0.001). At the time of the analysis, 83.8% of the patients had died. In the univariate analysis, the median OS (±SE) was significantly longer in the A group compared with the C group (21±4.2 vs 11 ±0.9 months, p= 0.004) (Fig 1). In addition to AmE usage, female gender, smoking status, presence of hypertension and erlotinib usage had also significant impact on OS (p <0.05 for all). In the multivariate analysis, only AmE (HR: 0.46, 95% CI: 0.27-0.76, p= 0.003) and erlotinib (HR: 0.45, 95% CI: 0.22-0.89, p= 0.02) usage had significant benefit on OS. Figure 1 Fig 1. The Kaplan-Meier curves of OS according to AmE usage.



      Conclusion:
      The use of AmE during systemic anti-cancer treatment may significantly prolong OS of patients with metastatic NSCLC.